This post was originally published on this site

Family Oddball, and a New Class of Safe Oral Autoimmune & Inflammatory Disease Treatment with Blockbuster Potential On day one of the JPM 2021 conference, CEO Giovanni Caforio of Bristol Myers Squibb – inheritor of Celgene’s former first presenting slot – took the virtual stage to highlight BMS’s biggest new products. By Jeb Keiper, CEORead More »

The post Selective Allosteric TYK2 Inhibitors appeared first on Atlas Venture.